Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Hapke

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Hastings Center Report|August 8, 2024
Experiential Training in Psychedelic-Assisted Therapy: A Risk-Benefit AnalysisDaniel Rosenbaum, Crystal Hare, Emma Hapke, et al.
Journal of Psychopharmacology (Oxford, England)|February 29, 2020
Microdosing psychedelics: Demographics, practices, and psychiatric comorbiditiesDaniel Rosenbaum, Cory Weissman, Thomas Anderson, et al.
Harm Reduction Journal|July 11, 2019
Psychedelic microdosing benefits and challenges: an empirical codebookThomas Anderson, Rotem Petranker, Adam Christopher, et al.
Psychopharmacology|January 4, 2019
Microdosing psychedelics: personality, mental health, and creativity differences in microdosersThomas Anderson, Rotem Petranker, Daniel Rosenbaum, et al.
Pilot and Feasibility Studies|October 29, 2025
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trialCandice Richardson, Cindy Chan, Emily Macgregor, et al.
Nature Medicine|May 11, 2021
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyJennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, et al.
Focus (American Psychiatric Publishing)|July 5, 2023
MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 StudyJennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Hastings Center Report|August 8, 2024
Experiential Training in Psychedelic-Assisted Therapy: A Risk-Benefit AnalysisDaniel Rosenbaum, Crystal Hare, Emma Hapke, et al.
Journal of Psychopharmacology (Oxford, England)|February 29, 2020
Microdosing psychedelics: Demographics, practices, and psychiatric comorbiditiesDaniel Rosenbaum, Cory Weissman, Thomas Anderson, et al.
Harm Reduction Journal|July 11, 2019
Psychedelic microdosing benefits and challenges: an empirical codebookThomas Anderson, Rotem Petranker, Adam Christopher, et al.
Psychopharmacology|January 4, 2019
Microdosing psychedelics: personality, mental health, and creativity differences in microdosersThomas Anderson, Rotem Petranker, Daniel Rosenbaum, et al.
Pilot and Feasibility Studies|October 29, 2025
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trialCandice Richardson, Cindy Chan, Emily Macgregor, et al.
Nature Medicine|May 11, 2021
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyJennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, et al.
Focus (American Psychiatric Publishing)|July 5, 2023
MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 StudyJennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, et al.
Pageof 1